
Sanofi
Sanofi is a France-based company in the Healthcare sector with a market capitalisation of $96.9B. Its FinScore is 68/100; its highest-scoring layer is Quality (85) and its lowest is Growth (33). The shares trade at 12.8x trailing earnings and are down 13% year to date.
Share price performance
About Sanofi
www.sanofi.comSanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- HQ
- France
- Fiscal year-end
- December
- Trading currency
- EUR
- Reporting currency
- EUR
- Fundamentals updated
- 80 days ago
- Market cap
- $96.9B
- Shares outstanding
- 1.2B
- P/E (TTM)
- 12.8x
- Dividend yield (TTM)
- 5.73%
- Beta (issuer)
- 0.28
- Revenue (latest FY)
- €43.6B
Revenue breakdown
- Reportable Geographical Zones76.4%€43.6B
- Europe16.1%€9.2B
- CHINA4.6%€2.6B
- FRANCE3.0%€1.7B
FinScore
As of 2026-10-19Snapshot
Ownership
Holder data is not available for this company yet.
Sign up or log in to see Analysis
Analysis for Sanofi is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Financials
Financials for Sanofi is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Estimates
Estimates for Sanofi is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Peers
Peers for Sanofi is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Valuation
Valuation for Sanofi is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see News
News for Sanofi is available to Finryse members. The Overview stays open to everyone; creating an account is free.